CLDX Celldex Therapeudics Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CLDX Celldex Therapeudics

CLDX 26.71

+2.7%

Oct 31 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: scaram(o)uche	12/9/2019 11:19:45 AM
	of 105

Novartis experience with moving (in this case, conjugated) anti-kit into clinic mirrored the CLDX experience with CDX-0158. CDX-0159 has, again, been engineered to eliminate Fc interactions and to extend half-life..... clincancerres.aacrjournals.org LOP628, a KIT targeted antibody drug conjugate (ADC), induced tumor regression in preclinical tumor models and had a tolerable safety profile in nonhuman primates thus supporting its clinical utility. Unexpectedly, three patients enrolled in a LOP628 phase I clinical trial experienced rapid hypersensitivity reactions (HSRs). Here we show that LOP628-mediated mast cell degranulation is likely the cause of the observed HSR and that the co-engagement of the Fc gamma receptor and KIT on mast cells is the underlying mechanism.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next